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Background
Tuberculosis (TB) is the leading cause of morbidity and
mortality among persons with HIV/AIDS in highly
affected regions including Russia. Despite the fact that
Russia has the infrastructure for the treatment of TB unlike
developing countries, authorities are not yet paying atten-
tion to provide antiretroviral treatment for these category
of people who are mostly IDU users, former prisoners and
jobless. As such the benefit of highly active antiretroviral
therapy (HAART) in the treatment of patients co-infected
with tuberculosis (TB) and human immunodeficiency
virus (HIV) has never been explored in this country.
Objective
To assess the risks and benefits of administering highly
active antiretroviral therapy (HAART) during the treat-
ment of tuberculosis (TB) in HIV-infected patients.
Materials and methods
53 HIV-infected persons diagnosed with active TB were
recruited in the special HIV and TB unit of the second city
tuberculosis hospital in Saint- Petersburg, Russia into an
observational, prospective study aimed to evaluate tuber-
culosis treatment outcomes between Dec.2003 and March
2005. Only 15 patients (28.3%) with a median CD4 cell
count of 235 cells/mm3 were on ART (AZT+3TC+EFV),
while the rest 38 (71.7%) with a median CD4 cell count
of 267 cells/mm3 received antituberculosis medications
only. Clinical and immunologic responses were assessed
within the two groups by comparing incidence of new
AIDS-associated opportunistic illnesses (OIs), adverse
events and CD4 cells dynamics.
Results
Among antiretroviral patients, CD4 cell count increased
to 297 cells/mm3 versus a decrease to 212 cell/mm3 in
patients on anti-tuberculosis treatment alone (p = 0.10).
The risk for HIV progression to new OIs was lower among
antiretroviral group (3.5 versus 24.5%; relative risk (RR) =
0.14. Adverse events (AE) occurred in 3 (20%) of the15
patients on antiretroviral, all with a CD4 cell count of <
100 cells/mm3 and one patient interrupted HIV medica-
tion. The majority of AE occurred within the first 2
months, with anemia, increased cough, rash and gastroin-
testinal upset occurring most commonly.
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Retrovirology 2005, 2:S135Conclusion
HAART substantially reduced new AIDS events and
improved CD4 cells count in HIV-TB co-infected patients.
Those with a CD4 cell count < 100 cells/mm3 have a high
event risk during the intensive phase of anti-TB treatment.
These pilot data should be taken into account when decid-
ing to initiate HAART in co-infected patients with CD4
cell counts < 100 cells/mm3.Page 2 of 2
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